For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- PII Results of Iressa Reported at ASCO
June 3, 2002
- We Are in Predawn of Radical Reform: Mr Nagayama of JPMA
June 3, 2002
- New Shionogi Cephem Antibiotic Shows Good Effects on MRSA
June 3, 2002
- Dainippon Licenses Ca Antagonist from Recordati
June 3, 2002
- Panasonic Develops High-throughput Drug Screening Technology
June 3, 2002
- Mitsubishi Chemical: Pharma Sales Up 81.3% to \231.1 Bil.
June 3, 2002
- OTC NEW IN BRIEF
June 3, 2002
- MPC: Radicut, Overseas Sales Boosts Sales, Profits
June 3, 2002
- DIAGNOSTIC NEWS IN BRIEF
June 3, 2002
- Tanabe's Mid-term Plan to Be Handed over to New President
June 3, 2002
- MEDICAL DEVICE NEWS IN BRIEF
June 3, 2002
- Sankyo, Sanwa Kagaku Tie Up on ARI, Ca Antagonist
June 3, 2002
- Combined Sales of 27 JPMA Member Firms Up 4.9% to \5,526 Bil.
June 3, 2002
- AstraZeneca, Shionogi to Comarket New Statin Crestor
June 3, 2002
- Yamanouchi: Sales Up 5.1% Thanks to Harnal, Lipitor
June 3, 2002
- Iressa to Be Approved in Japan before US, Europe
June 3, 2002
- Eisai: Overseas Sales Up 53%, Accounting for 42.9% of Total Sales
June 3, 2002
- Taiho Aims at Sales of \140 Bil. in 2004
June 3, 2002
- Daiichi: Record-high Sales, Profits Thanks to Cravit
June 3, 2002
- BUSINESS NEWS IN BRIEF
June 3, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…